Amplius Wealth Advisors’s SELLAS Life Sciences SLS Stock Holding History

Amplius Wealth Advisors’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5	Closed	–	–	769
2021 Q4	$0	Buy	+5	New	+$38	﹤0.01%	990

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Amplius Wealth Advisors's SLS Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of SELLAS Life Sciences (SLS) in Q1 2022, closing a stake of 5 shares.

Amplius Wealth Advisors first reported a position in SLS in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 26 funds tracked by Wall St. Rank hold SLS as of Q1 2022.

Amplius Wealth Advisors reported no remaining SELLAS Life Sciences position as of Q1 2022 after selling out during the quarter.
Amplius Wealth Advisors sold 5 SELLAS Life Sciences shares in Q1 2022.
Amplius Wealth Advisors first reported a position in SELLAS Life Sciences in Q4 2021 and held it in 1 quarter.
Amplius Wealth Advisors's SELLAS Life Sciences position peaked at $0 in Q4 2021.
26 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.